FMS - Fresenius Medical Care AG & Co. KGaA

NYSE - Nasdaq Real Time Price. Currency in USD
35.98
-0.16 (-0.44%)
As of 12:04PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close36.14
Open36.28
Bid35.98 x 800
Ask36.00 x 1800
Day's Range35.89 - 36.34
52 Week Range30.99 - 42.75
Volume65,453
Avg. Volume191,927
Market Cap21.371B
Beta (3Y Monthly)1.16
PE Ratio (TTM)9.75
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.66 (1.81%)
Ex-Dividend Date2019-05-17
1y Target EstN/A
  • Should Value Investors Buy Fresenius (FMS) Stock?
    Zacks

    Should Value Investors Buy Fresenius (FMS) Stock?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Is Fresenius Medical Care AG & Co. KGaA (ETR:FME) Trading At A 38% Discount?
    Simply Wall St.

    Is Fresenius Medical Care AG & Co. KGaA (ETR:FME) Trading At A 38% Discount?

    In this article we are going to estimate the intrinsic value of Fresenius Medical Care AG & Co. KGaA (ETR:FME) by...

  • Fresenius Medical (FMS) Q3 Earnings & Revenues Top Estimates
    Zacks

    Fresenius Medical (FMS) Q3 Earnings & Revenues Top Estimates

    Fresenius Medical's (FMS) Q3 earnings benefit from strong segmental performance and solid 2019 EPS outlook.

  • Jefferson Health expands kidney dialysis access in South Jersey through new partnership
    American City Business Journals

    Jefferson Health expands kidney dialysis access in South Jersey through new partnership

    Fresenius Kidney Care has formed a partnership with Jefferson Health to provide expanded access to dialysis for South Jersey residents living with kidney failure. Financial terms of the deal were not disclosed. Under the partnership, current Jefferson Health dialysis patients will continue to receive care from the same team of nephrology physicians and providers at the health system's outpatient locations in Voorhees and Washington Township.

  • Fresenius beats third-quarter forecasts with strong sales of home dialysis treatments
    Reuters

    Fresenius beats third-quarter forecasts with strong sales of home dialysis treatments

    The group said both Fresenius Medical Care , the world's largest provider of dialysis treatments, and drugmaker Kabi saw strong organic growth in Asia and Europe, more than offsetting weak U.S. markets. Shares in both Fresenius and Fresenius Medical Care were up about 4% in early trade on Tuesday. Analysts said investors were relieved that a summer slowdown at Helios and a further negative impact from a U.S. dialysis treatment coordination programme known as ESCO did not materialize.

  • Reuters

    UPDATE 3-Fresenius beats Q3 forecasts with strong sales of home dialysis treatments

    German healthcare group Fresenius beat third-quarter revenue forecasts on Tuesday, citing a solid performance by its infusion drugs unit in emerging markets and strong growth in home treatment at its separately listed dialysis business. The group said both Fresenius Medical Care, the world's largest provider of dialysis treatments, and drugmaker Kabi saw strong organic growth in Asia and Europe, more than offsetting weak U.S. markets. Fresenius confirmed its full-year guidance after third-quarter revenues rose by 8% to 8.9 billion euros ($9.86 billion) in the third quarter, compared to 8.7 billion euros in a company-compiled consensus.

  • Here's Why You Should Retain Ecolab (ECL) Stock For Now
    Zacks

    Here's Why You Should Retain Ecolab (ECL) Stock For Now

    Ecolab (ECL) continues to gain from robust product portfolio and strong international presence. However, forex remains a woe.

  • Is Fresenius Medical Care AG & Co. KGaA's (ETR:FME) P/E Ratio Really That Good?
    Simply Wall St.

    Is Fresenius Medical Care AG & Co. KGaA's (ETR:FME) P/E Ratio Really That Good?

    Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. We'll show how you can...

  • Hedge Funds Have Never Been This Bullish On Fresenius Medical Care AG & Co. KGaA  (FMS)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Fresenius Medical Care AG & Co. KGaA (FMS)

    Is Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but […]

  • Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
    Zacks

    Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now

    PerkinElmer (PKI) is gaining steadily from the core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.

  • Here's Why You Should Retain Cooper Companies (COO) Stock Now
    Zacks

    Here's Why You Should Retain Cooper Companies (COO) Stock Now

    Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex continues to remain a concern.

  • Is Fresenius (FMS) Stock Undervalued Right Now?
    Zacks

    Is Fresenius (FMS) Stock Undervalued Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Here's Why You Should Retain DaVita (DVA) Stock for Now
    Zacks

    Here's Why You Should Retain DaVita (DVA) Stock for Now

    DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, integration risks remain a concern.

  • Integer Holdings (ITGR) Boosts Product Line with New Buyout
    Zacks

    Integer Holdings (ITGR) Boosts Product Line with New Buyout

    Integer Holdings' (ITGR) buyout is likely to add differentiated capability for complex braided and formed biomedical structures to the company's existing product portfolio.

  • Does The Data Make Fresenius Medical Care AG & Co. KGaA (ETR:FME) An Attractive Investment?
    Simply Wall St.

    Does The Data Make Fresenius Medical Care AG & Co. KGaA (ETR:FME) An Attractive Investment?

    I've been keeping an eye on Fresenius Medical Care AG & Co. KGaA (ETR:FME) because I'm attracted to its...

  • Fresenius Medical Launches 4008A Dialysis Machine in China
    Zacks

    Fresenius Medical Launches 4008A Dialysis Machine in China

    Fresenius Medical (FMS) aims to treat ESRD patients in remote locations of China.

  • Should You Worry About Fresenius Medical Care AG  Co. KGaA's (ETR:FME) CEO Pay Cheque?
    Simply Wall St.

    Should You Worry About Fresenius Medical Care AG Co. KGaA's (ETR:FME) CEO Pay Cheque?

    Rice Powell became the CEO of Fresenius Medical Care AG & Co. KGaA (ETR:FME) in 2013. This report will, first, examine...

  • Zacks Small Cap Research

    CTSO: Q2 19: Product Sales Rebound to Record High Despite Distributor Hangover. Value-Inflection Opportunities Abound

    ‣ Record Revenue, Margins: Q2 set records on Product Revenue, Total Revenue, Direct Sales and Product Margin. CytoSorbents (CTSO) expects all three to be back online by year-end (one of which resumed ordering in Q2).

  • Is Fresenius Medical (FMS) a Good Value Investor Pick Now?
    Zacks

    Is Fresenius Medical (FMS) a Good Value Investor Pick Now?

    Let's see if Fresenius Medical (FMS) stock is a good choice for value-oriented investors right now from multiple angles.

  • Should You Be Impressed By Fresenius Medical Care AG & Co. KGaA's (ETR:FME) ROE?
    Simply Wall St.

    Should You Be Impressed By Fresenius Medical Care AG & Co. KGaA's (ETR:FME) ROE?

    One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

  • Cytosorbents (CTSO) Q2 2019 Earnings Call Transcript
    Motley Fool

    Cytosorbents (CTSO) Q2 2019 Earnings Call Transcript

    CTSO earnings call for the period ending June 30, 2019.

  • 3 Marijuana Stocks to Play the Future of Cannabis Medicine
    InvestorPlace

    3 Marijuana Stocks to Play the Future of Cannabis Medicine

    For many investors looking at marijuana stocks, the name of the game is consumerism. The play is betting on legalization and growing recreational consumer use. It's the reason why marijuana stocks like Canopy Growth (NYSE:CGC) surged on its partnership deal with Constellation Brands (NYSE:STZ). And there is a good reason to be bullish, recreational cannabis usage has the potential to be a multi-billion market over the next decades as more consumers jump onboard.Source: Shutterstock However, there may be a bigger play for investors when it comes to pot stocks. And that's in cannabis medicine.While medical marijuana usage isn't new, deriving new drugs from cannabis is and there are now several biopharma's looking into doing just that. The potential here is just as great as the consumer side. Perhaps even more so. According to research by BDS Analytics, the global medical marijuana market is projected to more than double from 2018 levels in just four short years. Cannabis medicine will be a big driver of that. Investors today have a huge runway of potential ahead of themselves.InvestorPlace - Stock Market News, Stock Advice & Trading TipsHowever, the medical marijuana sector isn't without risk. You basically are combining clinical-stage biotech investing with the volatility of marijuana stocks. But the rewards could be great. * 10 Cyclical Stocks to Buy (or Sell) Now If you have some risk capital to play with, the following three medical marijuana stocks could worth your while. GW Pharmaceuticals (GWPH)Source: GW Pharmaceuticals If you're going to bet on the future of cannabis medicine, why not go with a sure thing. While there are many biotech firms fighting to use cannabis in their drugs, only GW Pharmaceuticals (NASDAQ:GWPH) has one approval under its belt.Getting any drug through the Food and Drug Administration is an amazing feat and about a year ago, GWPH managed to score an approval for its cannabinoid-based drug Epidiolex. The treatment is used to prevent seizures associated with Lennox-Gastaut syndrome or Dravet syndrome.Back in November, the drug was officially launched and so far, it has been quite successful for GWPH. During the firm's reported first quarter, GWPH managed to see Epidiolex sales of $33.5 million. That was more than double analysts' estimates. This puts sales on pace to rake-in more than $150 million this year. Again, that's well above initial analyst estimates. The firm will report its next round of sales figures at the beginning of August.And the blockbusters could keep coming for GWPH. Phase III trial data for Epidiolex and seizures associated with tuberous sclerosis complex (TSC) have recently come in extremely strong. Given the statistical significance of the data, GWPH is looking at another approval for the drug very soon. That could only boost revenues further.Now, shares of GWPH stock are up around 60% year-to-date. But given its long-term potential and overall sales, more gains could be in store. Average analyst targets are about 37% high than its current share price. Cara Therapeutics Inc (CARA)Source: Shutterstock Also surging around 60% this year has been marijuana stock Cara Therapeutics (NASDAQ:CARA). However, unlike GWPH, CARA's rise has all been about the potential for approval.CARA is going after chronic kidney disease-associated pruritus (CKD-aP). Pruritus is a fancy way of saying pain and itching. But for those who suffer from the issue, it can be pretty debilitating. And right now, there isn't a treatment for this instance of the problem. The reason for the investors' enthusiasm is that CARA has been able to see some big initial results from Phase I trials for its drug Korsuva. Phase III trials for the drug should wrap up later this year and given the results so far, CARA could be looking at an approval.That could be big news for the marijuana stock. Over 30 million people have chronic kidney disease (CKD) and analysts project that Korsuva could achieve peak annual sales of more than $570 million. The drug developer has already signed up dialysis specialist Fresenius Medical Care (NYSE:FMS) as a partner to market the drug in its nearly 4,000 centers. Meanwhile, CARA is looking to expand Korsuva beyond injections and into an oral form. That could expand potential sales even further. * 7 Stocks the Insiders Are Buying on Sale All in all, CARA is on a path to approval, has a big addressable market and a plan to grow sales. For investors, the clinical-stage biotech stock could be a good bet for the future of cannabis medicine. Zynerba Pharmaceuticals Inc (ZYNE)Source: Zynerba PharmaceuticalsZynerba Pharmaceuticals (NASDAQ:ZYNE) investors have experienced a staggering gain of 350% this year. And there is plenty of real, lasting "oomph" behind the gains.ZYNE only has one drug candidate -- Zygel -but it is a doozy. The medicine is a cannabidiol (CBD) gel being targeted toward treating seizures and behavioral symptoms associated with neuropsychiatric disorders. We're talking autism and Fragile X syndrome.As a gel, the potential is huge. One of the issues with oral cannabis medications is that they can cause all sorts of gastrointestinal side effects and other liver problems. These problems can build-up over time and for children it can be problematic in the future after years of medicine usage. The firm received a patent for the product last month.Trials are ongoing as well. ZYNE should wrap-up Phase III trials for Zygel for Fragile X at the end of 2019 and file a new drug application during the first half of 2020. The biotech is also conducting phase II trials for the gel for autism. Given the size of the addressable market and the potential for the gel to be a wonder drug for symptoms, the surge in Zynerba could be justified.It's certainly the riskiest of the marijuana stocks on this list, but the firm does have plenty of cash on its balance sheet to make it through its current round of trials and into marketing. And with a small market-cap, there are still plenty of gains to be had.As of this writing, Aaron Levitt did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Cyclical Stocks to Buy (or Sell) Now * 7 Biotech ETFs That Should Remain Healthy * 7 of the Hottest AI Stocks to Buy Now The post 3 Marijuana Stocks to Play the Future of Cannabis Medicine appeared first on InvestorPlace.